Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 6

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 6
---
.1 |     |     |          |  21.2 | % |     |          |     |  17.2 | %                         |
| Vaccines      |          |                           |    50.4 |     |     |    55.4 |     |     |                  |     |   5.1 |     |     |          |  10.0 | % |     |          |     |   7.5 | %                         |
| Neuroscience  |          |                           |   627.0 |     |     |   565.8 |     |     |                  |     | -61.2 |     |     |          |  -9.8 | % |     |          |     | -14.1 | %                         |
| Other         |          |                           |   315.7 |     |     |   257.4 |     |     |                  |     | -58.3 |     |     |          | -18.5 | % |     |          |     | -20.0 | %                         |
| Total         |          |                           | 4,263.8 |     |     | 4,581.6 |     |     |                  |     | 317.8 |     |     |          |   7.5 | % |     |          |     |   2.9 | %                         |

Year-on-year change in revenue for this fiscal year in each of our business areas was primarily attributable to the following products:

#### GI
In GI, revenue was JPY 1,357.0 billion (JPY +140.8 billion and +11.6% AER, +6.8% CER).

Sales of ENTYVIO (for ulcerative colitis (“UC”) and Crohn’s disease (“CD”)) were JPY 914.1 billion (JPY +113.2 billion and +14.1% AER, +8.5% CER). Sales in the U.S. were JPY 619.2 billion (JPY +73.1 billion and +13.4% AER). The increase was due to maintaining strong demand in the first line biologic inflammatory bowel disease (“IBD”) population and continued patient gains after the launch of the subcutaneous formulation, as well as favorable foreign exchange rates. Sales in Europe and Canada were JPY 227.4 billion (JPY +